Join Jeff Blaney (Genentech), Darren Green (GSK) Julian Levell (New Equilibrium Biosciences) and Matt Segall (Optibrium), for this panel on the state of AI in early drug discovery from hit to preclinical candidate. The panellists will share their experiences with and expectations of AI, including predictive modelling, synthesis prediction and generative chemistry. Hear about the successes of AI and an outlook on what AI needs to achieve to really transform drug discovery.
Host: Tim Hohm, Director of Commercial Strategy and Business Development,
Matt Segall, CEO, Optibrium
Darren Green, Head of Cheminformatics & Data Science, GSK
Jeff Blaney, Senior Director of Discovery Chemistry ,Genentech
Julian Levell, Head of Discovery, New Equilibrium Biosciences